toxylact: a07bc04 Attapulgite

The first professional lActological database in the word

Attapulgite (ATC A07BC04) is a non‑absorbed magnesium aluminium silicate clay classified as an “other intestinal adsorbent”, used for short‑term symptomatic treatment of acute, non‑infectious diarrhea, with negligible systemic absorption and a very low expected risk during breastfeeding.atcddd.fhi+3

ATC A07BC04 overview

ATC code A07BC04 designates attapulgite within the subgroup A07BC “Other intestinal adsorbents”, part of the intestinal adsorbents class A07B among antidiarrheals. It is formulated in suspensions or tablets for oral use and is often marketed under various brand names as an over‑the‑counter antidiarrheal for adults and children.atcddd.fhi+5

Pharmacology and mechanism

Attapulgite is a naturally occurring clay (palygorskite) with a fine particle size and porous structure that confers high adsorptive capacity for water, bacteria, and toxins in the gastrointestinal lumen. By binding these substances and forming a gel‑like coating on the intestinal mucosa, it reduces water loss, increases stool consistency, and helps alleviate cramping associated with acute diarrhea.sciencedirect+3youtube

Therapeutic indications

Within A07BC04, attapulgite is indicated for short‑term symptomatic treatment of mild‑to‑moderate acute, non‑specific or non‑infectious diarrhea, often as an adjunct to oral rehydration therapy. Clinical trials have shown that attapulgite reduces stool frequency, improves stool consistency, and decreases dehydration severity and oral rehydration solution use compared with placebo in adult acute diarrhea.pubmed.ncbi.nlm.nih+3

Dosage and administration context

Adults and adolescents typically receive 1.2–1.5 g per dose after each loose stool, up to about 8.4 g per day, while lower age‑adjusted doses are used in children. It is recommended for short‑term use only, with instructions to seek medical evaluation if diarrhea persists, is accompanied by fever or blood, or if significant dehydration develops.medicinenet+1youtube

Pharmacokinetics relevant to lactation

Attapulgite is an oral, non‑absorbed medication; it acts locally in the gut and is excreted unchanged in feces, with no meaningful systemic bioavailability. Because it does not enter maternal circulation, the presence of attapulgite in human milk is considered unlikely, and any transfer would be toxicologically negligible.sciencedirect+2

Maternal safety and adverse effects

Attapulgite is generally well tolerated when used short‑term; constipation is the most common adverse effect, and bloating, flatulence, stomach upset, or nausea may also occur. It should not be used in patients with suspected bowel obstruction or severe constipation, and, like other adsorbents, it can reduce absorption of concomitant oral drugs if taken simultaneously, so dose separation is advisable.youtubesciencedirect+1

Lactation safety assessment

Reference sources note that attapulgite is not absorbed, so its presence in breast milk is unlikely, and its use is generally accepted as safe during breastfeeding. General breastfeeding‑and‑medication guidance likewise considers non‑absorbed intestinal adsorbents to be among the lowest‑risk therapies for lactating women, provided they are used short‑term and at recommended doses.who+4

Potential effects on the breastfed infant

Because attapulgite does not reach maternal plasma, direct exposure of the infant via milk is expected to be extremely low, and attapulgite‑related toxicity in the breastfed infant is not anticipated. Any concern for the infant is more likely related to the underlying maternal illness (for example infectious diarrhea) or dehydration than to the drug itself, so clinical attention should focus on maternal assessment and infection‑control measures.sciencedirect+4

Practical recommendations in breastfeeding

For breastfeeding women with mild, acute diarrhea without systemic red‑flag signs, attapulgite can be considered as a short‑term symptomatic option alongside oral rehydration, with no need to interrupt or time breastfeeding in relation to doses. As with other antidiarrheals, the lowest effective dose and shortest duration should be used, interacting medications should be reviewed because of potential adsorption, and the infant should be observed for general well‑being and signs of transmitted infection rather than drug effects.sps+3

Role among intestinal adsorbents

Compared with other A07BC adsorbents, attapulgite has relatively strong sorptive capacity and documented clinical efficacy in adult acute diarrhea, while retaining the favorable safety profile typical of non‑absorbed clays. This combination of local effectiveness, negligible systemic exposure, and good lactation compatibility supports its classification as a low‑risk antidiarrheal option in breastfeeding when used appropriately and short‑term.pubmed.ncbi.nlm.nih+5

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.